Norwood, MA (PRWEB) January 09, 2012
BioPharm Insight™ Global Editor Kimberly Ha will moderate an expert panel discussion on biotechnology investment trends at OneMedForum SF 2012 on January 11, 2012, at 8:00am PST. The panel will cover major developments in topics such as:
- Regenerative medicine
- Neurological disorders
- Infectious diseases
The panel will also discuss which therapeutic areas of development will see the most investment activity, as well as how companies should best position themselves for a strategic exit as large pharma seeks to boost pipelines by finding innovative new targets and compounds.
Distinguished subject matter experts participating in the panel include:
- Tim Opler, Ph.D, Principal at Torreya Partners
- Les Funtleyder, MPH, Healthcare Strategist at Miller Tabak + Co
- Andrew McDonald, Ph.D, founder of LifeSci Advisors.
BioPharm Insight subscribers are invited to attend OneMedForum SF 2012 for free. Please contact Marketing Director Kris Sarajian at ksarajian(at)infinata(dot)com for details.
To view the full agenda and register for OneMedForum SF 2012, hosted by OneMedPlace, visit http://www.onemedplace.com/forum.
About BioPharm Insight
BioPharm Insight is the definitive guide to the global biopharma community. BioPharm Insight provides clients with an information edge by combining the most comprehensive real-time database of companies, drugs, contacts, M&A and licensing deals, forecasts and clinical trial data with proprietary forward-looking intelligence uncovered by an independent team of investigative journalists months or even years before it breaks in mainstream media. To learn more, visit http://www.biopharminsight.com.
About Infinata, Inc.
Featuring a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services, Infinata provides personalized technology solutions to turn information into insight. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson plc. To learn more, visit http://www.infinata.com.